Table 2 Characteristics of andexanet alpha-induced heparin resistance
Total, n | 10 cases |
|---|---|
Age (year) median (range) | 73.5 (46–87) |
Sex, male; n (%) | 5 (50.0) |
Body weight (kg) median (range) | 76 (50–120) |
Direct oral anticoagulants | |
Apixaban, n (%) | 5 (50.0) |
Edoxaban, n (%) | 3 (30.0) |
Rivaroxaban, n (%) | 2 (20.0) |
Surgical diagnosis | |
Stanford type A acute aortic dissection, n (%) | 7 (70.0) |
Ruptured abdominal aortic aneurysm, n (%) | 2 (20.0) |
Left ventricular free wall rupture, n (%) | 1 (10.0) |
Emergency surgery, n (%) | 10 (100.0) |
Andexanet alfa administration | |
Before surgery | 9 (90.0) |
During cardiopulmonary bypass | 1 (10.0) |
Dose of andexanet alfa (mg) | |
800 mg IV + 8 mg/min div | 1 (10.0) |
400 mg IV + 4 mg/min div | 8 (80.0) |
Treatment for heparin resistance | |
Heparin addition, n (%) | 10 (100.0) |
Inefficacy of heparin addition, n (%) | 9 cases in 10 cases (90.0) |
Fresh frozen plasma, n (%) | 2 (20.0) |
Inefficacy of fresh frozen plasma, n (%) | 2 cases in 2 cases (100.0) |
Antithrombin, n (%) | 4 (40.0) |
Inefficacy of antithrombin, n (%) | 1 case in 4 cases (25.0) |
Nafamostat mesilate, n (%) | 2 (20.0) |
Inefficacy of nafamostat mesilate, n (%) | 0 case in 2 cases (0.0) |
Complication of thrombus, n (%) | 3 (30.0) |